Skip to main content

Multicentre trials in drug development: good? necessary?

  • Chapter
  • 15 Accesses

Abstract

Fifteen years ago, when the first International Meeting of Pharmaceutical Physicians (IMPP) took place in London, multicentre trials received only a marginal mention in one paper, that of McNicol [1], an investigator from academe, who in his conclusions emphasized their difficulties. Curiously enough, the same difficulties were expressed by Temple of the Food and Drug Administration in 1986 [2]. Thus, even though multicentre trials have reached a high degree of popularity nowadays, the subject is still controversial.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. McNicol G P. In: Jouhar A J, Grayson M F, eds. International Aspects of Drug Evaluation and Usage, Edinburgh and London: Churchill Livingstone, 1973;293–300.

    Google Scholar 

  2. Temple R. Effective design of clinical studies. Drug info J 1986;20:127–33.

    Google Scholar 

  3. Joyce C R B. In: Lucchelli P E, Bergamini N, Bachini V, eds. Rationality of Drug Development, Amsterdam and New York: Excerpta Medica, 1976; 17–20.

    Google Scholar 

  4. Lucchelli P E, Baroni L, Basagni M. Analisi del giudizio clinico in reumatologia. In: Fuccella L M, ed. Farmaci antiinfiammatori. Aspetti della valutazione preclinica e clinica, Milano: Informedica, 1977; 133–41.

    Google Scholar 

  5. Gruppo Italiano per lo Studio della Streptochinasi nell’ Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397–402.

    Google Scholar 

  6. Lucchelli P E, Motolese M. Aspetti metodologici ed organizzativi delle ricerche policentriche. Boll Chim Farm 1972;111:83–92.

    Google Scholar 

  7. Polli E, Barbieri D, Bonomo E, et al. Sperimentazione policentrica pianificata con diuretici nella cirrosi epatica ascitogena. Atti Accad Med Lomb 1963;18:1065–89.

    Google Scholar 

  8. Lucchelli P E. Clinical trials and the general practioner. In: Steichele C, Abshagen U, Koch-Weser J, eds. Drugs between Research and Regulations, New York: Steinkopff Verlag Darmstadt, Springer-Verlag, 1985;51–6.

    Chapter  Google Scholar 

  9. Sylvester R J, Pinedo HM, De Pauw M, et al. Quality of institutional participation in multicentre clinical trials. N Engl J Med 1981;305:852–5.

    Article  Google Scholar 

  10. Pace F, Blum A L. The multicentre trial: does it solve or create problems? Ital J Gastroenter 1981;13:260–7.

    Google Scholar 

  11. De Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177–88.

    Article  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Copyright information

© 1988 The International Federation of Associations of Pharmaceutical Physicians

About this chapter

Cite this chapter

Lucchelli, P.E. (1988). Multicentre trials in drug development: good? necessary?. In: Burley, D., Haward, C., Mullinger, B. (eds) The Focus for Pharmaceutical Knowledge. Palgrave, London. https://doi.org/10.1007/978-1-349-09571-1_14

Download citation

Publish with us

Policies and ethics